source
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partnersHengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom. In May the company signed a $15.2 billion licensing pact with…
- Viatris to acquire Pacira BioSciences for $1.65 billion to expand non‑opioid pain portfolioViatris announced a $1.65 billion acquisition of Pacira BioSciences, aiming to broaden its non‑opioid pain‑relief offerings. The deal includes Pacira's marketed products Exparel and Zilretta, which…